Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer

Ribic, C., Sargent, D.J., Moore, M.J., Thibodeau, S.N., French, A.J., Goldberg, R.M., Hamilton, S.R., Laurent‐Puig, P., Gryfe, R., Shepherd, L.E., Tu, D., Redston, M., &amp; Gallinger, S. (2003). Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. <em>New England Journal of Medicine</em>. https://doi.org/10.1056/nejmoa022289

Ribic C, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. New England Journal of Medicine. 2003. doi:10.1056/nejmoa022289.

@article{christine2003TumorM, title = {Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer}, author = {Christine Ribic and Daniel J. Sargent and Malcolm J. Moore and Stephen N. Thibodeau and Amy J. French and Richard M. Goldberg and Stanley R. Hamilton and Pierre Laurent‐Puig and Robert Gryfe and Lois E. Shepherd and Dongsheng Tu and Mark Redston and Steven Gallinger}, journal = {New England Journal of Medicine}, year = {2003}, doi = {10.1056/nejmoa022289}, }